Developing animal models for immunotherapy is often difficult due to the complexity of the immune system and tumor biology. Showcased in April’s GEN Magazine, Biocytogen presents a line of target-humanized mice models, covering a growing portfolio of immune checkpoints and cytokines alongside its flagship RenMab fully human antibody mouse. Biocytogen has also developed the immunodeficient B-NDG mice and associated tumor models suited for the investigation of in vivo mechanisms behind xeno-GVHD and antibody efficacy.
